Comparative Pharmacology
Head-to-head clinical analysis: ATOVAQUONE versus FEXINIDAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATOVAQUONE versus FEXINIDAZOLE.
ATOVAQUONE vs FEXINIDAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atovaquone is a hydroxynaphthoquinone that selectively inhibits mitochondrial electron transport chain complex III (cytochrome bc1 complex) in parasites, thereby disrupting pyrimidine synthesis and energy metabolism.
Fexinidazole is a nitroimidazole derivative that enters the parasite and inhibits DNA synthesis by forming reactive metabolites, leading to cell death. It is active against Trypanosoma brucei gambiense.
750 mg oral suspension twice daily for treatment of mild-to-moderate Pneumocystis jirovecii pneumonia; 1500 mg oral suspension once daily for prophylaxis.
500 mg orally twice daily for 10 days for trichomoniasis; 2 g orally single dose for giardiasis.
None Documented
None Documented
Clinical Note
moderateAtovaquone + Indinavir
"The serum concentration of Indinavir can be decreased when it is combined with Atovaquone."
Clinical Note
moderateAtovaquone + Artemether
"The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Artemether."
Clinical Note
moderateAtovaquone + Lumefantrine
"The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Lumefantrine."
Clinical Note
moderateAtovaquone + Dapsone
Terminal elimination half-life is approximately 2-3 days (67 hours) in adults, prolonged in renal or hepatic impairment.
Approximately 8-12 hours in adults; prolonged in hepatic impairment.
Primarily fecal (>94%) as unchanged drug; renal excretion is minimal (<1%).
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal.
Category A/B
Category C
Antiprotozoal
Antiprotozoal
"The risk or severity of adverse effects can be increased when Atovaquone is combined with Dapsone."